Julie joined GSK and was appointed as Chief Financial Officer Designate on 3 April 2023. She was appointed to the Board as Chief Financial Officer on 1 May 2023. She is a member of the GSK Leadership Team.
Julie has an extensive financial and life sciences background, having been the Group CFO of Smith & Nephew from 2013 to 2017 and serving as a Non-Executive Director and Audit Chair of Roche Holding AG from 2016 to 2022. Before this, Julie was Interim Group CFO of AstraZeneca plc, having worked in a wide range of commercial, strategic and financial positions across three continents over a 25 year period. Julie was also Chief Operating Officer and CFO and Executive Director of Burberry Group plc from 2017 to 2023, where her responsibilities included Finance, Transformation, Information Technology and oversight of cyber security.
Julie is a Fellow of the Institute of Chartered Accountants and the Institute of Tax.
External appointments:
- Co-Chair, CFO Leadership Network, Accounting for Sustainability (part of the King Charles III Charitable Fund Group of Companies)
- Patron, Oxford University Women in Business
- Non-Executive Director and Chair of the Audit Committee, Diageo plc (effective 5 August 2024)
Follow Julie on LinkedIn
